Remix Therapeutics

Remix Therapeutics discovers and develops small molecules that modulate RNA processing to control gene and protein expression. Its proprietary REMaster platform combines data science, functional target validation, multiplexed high-throughput screening and computational chemistry. Its lead program, REM-422, is an investigational oral small-molecule mRNA degrader targeting MYB, a transcription factor implicated in adenoid cystic carcinoma and AML/MDS, and is in Phase 1 clinical trials.

The company's pipeline is focused on oncology and neurodegenerative diseases. In March 2026 the FDA granted REM-422 Fast Track designation for recurrent, metastatic or unresectable adenoid cystic carcinoma. In June 2026 Remix announced a merger agreement with Passage Bio, under which the combined company will operate as Remix Therapeutics, together with a concurrent $100 million private placement.

Remix launched in 2020 and is based in Watertown, Massachusetts. It has eight open roles, all in Watertown, spanning nonclinical drug safety and toxicology, GCP quality, clinical and commercial supply chain, medical affairs, companion diagnostics, commercial launch, clinical pharmacology and clinical data management.

Product: REM-422, an investigational oral small-molecule mRNA degrader targeting MYB, and the REMaster drug discovery platform.